Nektar Therapeutics (NKTR) News
Track canonical SquawkNews coverage tagged to NKTR, Nektar Therapeutics. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 24 indexed stories across 13 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
NKTR Stock Plunges on Rezpegaldesleukin Data; William Blair Maintains Durability View
Nektar Therapeutics (NKTR) shares dropped 21% on Thursday after the company presented new response rate data for its experimental skin drug, rezpegaldesleukin. While the drug reportedly maintained efficacy after treatmen
EQUITY | Oct 01, 2026, 07:42 PM UTC
L
Weekly Recap: Phase 3 ZENITH AD trials and $90M jury award
Nektar Therapeutics (NASDAQ:NKTR) is advancing rezpegaldesleukin with two global Phase 3 ZENITH AD trials (a third planned) even as Wedbush flags safety/efficacy concerns and a $50 target, the company won a $90M jury awa
NEWS | Sep 28, 2026, 11:04 AM UTC
L
Nektar Therapeutics Price Target Maintained With a $178.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 10:11 AM UTC
L
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00.The price target implies an upside of 212.0% from the Sep 25 close of $57.06.Key takeaways from the analyst noteStrong Clinic
EQUITY | Sep 28, 2026, 10:01 AM UTC
L
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 25, 2026 // -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock op
EQUITY | Sep 25, 2026, 08:15 PM UTC
H
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says
By Blake BrittainA federal jury in California has determined that Eli Lilly NYSE:LLY must pay Nektar Therapeutics NASDAQ:NKTR $90 million for breaking an agreement related to an autoimmune drug candidate that the compani
NEWS | Sep 25, 2026, 03:14 PM UTC
L
Nektar Therapeutics Price Target Maintained With a $178.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 02:42 PM UTC
L
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00.The price target implies an upside of 199.8% from the Sep 24 close of $59.38.Key takeaways from the analyst noteStrong Safety
EQUITY | Sep 25, 2026, 02:32 PM UTC
L
Nektar Gets $90 Million Jury Award in Breach Suit Against Eli Lilly — Update
By Colin KellaherNektar Therapeutics said it has won a $90 million verdict in its lawsuit against Eli Lilly related to the development of its proposed autoimmune drug rezpegaldesleukin, or rezpeg.Nektar on Friday said a
REGULATION | Sep 25, 2026, 01:37 PM UTC
L
Nektar Gets $90 Million Jury Award in Breach Suit Vs Eli Lilly
By Colin KellaherNektar Therapeutics said it has won a $90 million verdict in its lawsuit against Eli Lilly related to the development of its proposed autoimmune drug Rezpegaldesleukin, or rezpeg.Nektar said a California
REGULATION | Sep 25, 2026, 12:09 PM UTC
L
Nektar Therapeutics awarded $90M jury verdict against Eli Lilly over rezpegaldesleukin dispute
Nektar Therapeutics won a $90 million jury verdict finding Eli Lilly breached the implied covenant under their rezpegaldesleukin license agreement.Key Highlights:Original SEC Filing: NEKTAR THERAPEUTICS [ NKTR ] - 8-K -
REGULATION | Sep 25, 2026, 11:04 AM UTC
L
Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement
Eli Lilly and Company NYSE:LLY
NEWS | Sep 25, 2026, 11:03 AM UTC
L
Nektar Therapeutics Is Maintained at Neutral by Wedbush
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 12:29 PM UTC
L
Wedbush maintains Neutral rating on Nektar Therapeutics, $50 price target
Wedbush maintained their Neutral rating on Nektar Therapeutics's stock with a price target of $50.00.The price target implies a downside of 18.0% from the Sep 22 close of $60.97.Key takeaways from the analyst noteConcern
EQUITY | Sep 23, 2026, 12:19 PM UTC
L
Nektar Therapeutics price target maintained at $178 by BTIG
BTIG maintained a $178.00/share price target for Nektar Therapeutics.
EQUITY | Sep 09, 2026, 10:29 AM UTC
L
Nektar enters quiet period ahead of REZOLVE-AA follow-up data
Nektar said its quiet period began Sept. 8, 2026, ahead of 24-week off-treatment follow-up data from the Phase 2b REZOLVE-AA study of rezpegaldesleukin.
REGULATION | Sep 08, 2026, 08:13 PM UTC
L
Nektar Therapeutics reports inducement grants under Nasdaq Rule 5635(c)(4)
Nektar Therapeutics (NKTR) reports inducement grants under Nasdaq listing rule 5635(c)(4).
EQUITY | Aug 28, 2026, 08:18 PM UTC
L
Nektar (NKTR) publishes positive Phase 2b REZOLVE-AD 16-week results in The Lancet
Nektar announces publication in The Lancet of positive Phase 2b REZOLVE-AD 16-week induction results for rezpegaldesleukin in moderate-to-severe atopic dermatitis.
EQUITY | Aug 25, 2026, 12:30 PM UTC
L
JPMorgan initiates NKTR at Neutral with $65 price target
JPMorgan initiates coverage of NKTR with a Neutral rating and a $65.00 price target.
EQUITY | Aug 21, 2026, 11:58 AM UTC
L
Nektar Therapeutics reports Second Quarter 2026 financial results
Nektar Therapeutics (NKTR) announces its Second Quarter 2026 financial results, but the feed provides no further figures or guidance details.
EARNINGS | Aug 13, 2026, 08:15 PM UTC
L
NKTR NKTR - Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
NKTR NKTR - Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
EARNINGS | Jul 28, 2026, 10:00 PM UTC
L
NKTR Maintain Buy and $151 PT after Ph3 Initiation in Ad Marks Key Milestone for Rezpeg @ Citi
NKTR Maintain Buy and $151 PT after Ph3 Initiation in Ad Marks Key Milestone for Rezpeg @ Citi
EQUITY | Jul 22, 2026, 01:08 PM UTC
L
NKTR Initiated Buy W/$153.00 PT at Canaccord
NKTR Initiated Buy W/$153.00 PT at Canaccord
EQUITY | Jul 22, 2026, 12:02 PM UTC
L
NKTR Nektar Therapeutics announces start of phase 3 zenith Ad program evaluating novel regulatory T-cell biologic rezpegaldesleukin in moder
NKTR Nektar Therapeutics announces start of phase 3 zenith Ad program evaluating novel regulatory T-cell biologic rezpegaldesleukin in moderate-to-severe atopic dermatitis Nektar Therapeutics - initial phase 3 topline da
EQUITY | Jul 21, 2026, 11:04 AM UTC